169 related articles for article (PubMed ID: 23183425)
1. Eltrombopag inhibition of acute myeloid leukemia cell survival does not depend on c-Mpl expression.
Sugita M; Kalota A; Gewirtz AM; Carroll M
Leukemia; 2013 Apr; 27(5):1207-10. PubMed ID: 23183425
[No Abstract] [Full Text] [Related]
2. The new thrombopoietic agenda: impact on leukemias and MDS.
Bussel JB
Best Pract Res Clin Haematol; 2014; 27(3-4):288-92. PubMed ID: 25455280
[TBL] [Abstract][Full Text] [Related]
3. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome.
Will B; Kawahara M; Luciano JP; Bruns I; Parekh S; Erickson-Miller CL; Aivado MA; Verma A; Steidl U
Blood; 2009 Oct; 114(18):3899-908. PubMed ID: 19710504
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
Platzbecker U; Wong RS; Verma A; Abboud C; Araujo S; Chiou TJ; Feigert J; Yeh SP; Götze K; Gorin NC; Greenberg P; Kambhampati S; Kim YJ; Lee JH; Lyons R; Ruggeri M; Santini V; Cheng G; Jang JH; Chen CY; Johnson B; Bennett J; Mannino F; Kamel YM; Stone N; Dougherty S; Chan G; Giagounidis A
Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043
[TBL] [Abstract][Full Text] [Related]
5. Eltrombopag for chronic immune thrombocytopenia.
Milosevic I; Slade E; Drysdale H;
Lancet; 2016 Jan; 387(10016):336. PubMed ID: 26842445
[No Abstract] [Full Text] [Related]
6. Eltrombopag: Investigation of Previously Reported Serum Discoloration and Negative Interference on a Total Bilirubin Diazo Method.
Adams DF; Sellers TS
Arch Pathol Lab Med; 2016 May; 140(5):391-2. PubMed ID: 27128294
[No Abstract] [Full Text] [Related]
7. What is publication? The case of eltrombopag.
Benham L; Guo L; Turner R
Lancet; 2011 Jan; 377(9763):360-1. PubMed ID: 21277427
[No Abstract] [Full Text] [Related]
8. Eltrombopag for chronic immune thrombocytopenia - Authors' reply.
Grainger JD;
Lancet; 2016 Jan; 387(10016):336-337. PubMed ID: 26842444
[No Abstract] [Full Text] [Related]
9. Eltrombopag in thrombocytopenia.
Zimmer J; Hentges F; Andrès E
N Engl J Med; 2008 Mar; 358(10):1072; author reply 1072-3. PubMed ID: 18326076
[No Abstract] [Full Text] [Related]
10. Eltrombopag--an oral thrombopoietin agonist.
Sharma V; Randhawa H; Sharma A; Aggarwal S
Eur Rev Med Pharmacol Sci; 2012 Jun; 16(6):743-6. PubMed ID: 22913204
[TBL] [Abstract][Full Text] [Related]
11. Eltrombopag in thrombocytopenia.
Lawson A
N Engl J Med; 2008 Mar; 358(10):1072; author reply 1072-3. PubMed ID: 18322290
[No Abstract] [Full Text] [Related]
12. [Safety and efficacy of the use of eltrombopag in a case of severe acquired bone marrow aplasia].
Rubio-San-Simón A; Lázaro Rodríguez I; Vázquez Gómez F; Vivanco Martínez JL; Pérez Alonso V
An Pediatr (Engl Ed); 2019 Apr; 90(4):246-247. PubMed ID: 29798814
[No Abstract] [Full Text] [Related]
13. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.
Violi F; Pignatelli P
N Engl J Med; 2012 Nov; 367(21):2056. PubMed ID: 23171115
[No Abstract] [Full Text] [Related]
14. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.
Lisman T; Porte RJ
N Engl J Med; 2012 Nov; 367(21):2055-6. PubMed ID: 23171114
[No Abstract] [Full Text] [Related]
15. Successful treatment of severe thrombocytopenia with the use of thrombopoeitin receptor agonist eltrombopag in a patient with chronic myelomonocytic leukemia.
Modi Y; Shaaban H; Gauchan D; Maroules M
J Oncol Pharm Pract; 2015 Feb; 21(1):74-5. PubMed ID: 25063763
[TBL] [Abstract][Full Text] [Related]
16. Molecule of the month. Eltrombopag.
Drug News Perspect; 2008; 21(6):344. PubMed ID: 18836592
[No Abstract] [Full Text] [Related]
17. Eltrombopag use in higher risk myeloid cancers: fitting a square "pag" into a round hole?
Buckstein R
Lancet Haematol; 2019 Mar; 6(3):e111-e112. PubMed ID: 30704924
[No Abstract] [Full Text] [Related]
18. Longitudinal evaluation of eltrombopag in paediatric acquired severe aplastic anaemia.
Filippidou M; Avgerinou G; Tsipou H; Tourkantoni N; Katsibardi K; Vlachou A; Roka K; Solomou E; Kattamis A
Br J Haematol; 2020 Aug; 190(3):e157-e159. PubMed ID: 32529633
[No Abstract] [Full Text] [Related]
19. Usage of eltrombopag for chronic immune thrombocytopenia as a pretreatment for splenectomy.
Uwagawa T; Misawa T; Furukawa K; Ito R; Futagawa Y; Yahagi Y; Aiba K; Yanaga K
Acta Haematol; 2013; 129(1):45-7. PubMed ID: 23128016
[No Abstract] [Full Text] [Related]
20. [Development of myelofibrosis during eltrombopag treatment in a patient with immune thrombocytopenia].
Horikoshi A; Tsukuda J; Abe R; Fujiwara N; Ito E; Takaku T
Rinsho Ketsueki; 2016 May; 57(5):638-41. PubMed ID: 27263792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
